BioSpace News Archive

Three Finnish biotech companies - Abacus Diagnostica, Kaivogen and Labrox - are joining forces to form an international frontrunner in in vitro diagnostics.

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors.

Cloud computing is one of the most commonly used applications in healthcare. Healthcare organizations are highly concerned about the privacy and security of patient information, and the pressure of managing the growing healthcare data has driven the implementation of cost effective solutions such as cloud computing.

According to the report, the global disposable syringes market was valued at US$ 6.9 Bn in 2019 and is expected to expand at a CAGR of ~7% during the forecast period from 2020 to 2030.

According to the report, the global addiction treatment market was valued at ~US$ 6 Bn in 2019 and is projected to expand at a CAGR of ~6% from 2020 to 2030.

Harbour BioMed announced that the China National Medical Products Administration has approved its Investigational New Drug applications for HBM4003, a next-generation, fully human anti-CTLA-4 monoclonal heavy chain only antibody in combination with PD-1 antibody in patients with advanced hepatocellular carcinoma and other solid tumors, as well as advanced neuroendocrine tumor/neuroendocrine carcinoma and other solid tumors.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine & Tobacco Conference to be held virtually September 15-17, 2021.

Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that clinical data will be presented at the upcoming 2021 European Society of Medical Oncology Virtual Congress, taking place on September 16-21, 2021.

Exact Sciences Corp., a global leader in cancer diagnostics, announced that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project, a cooperative group founded by the National Cancer Institute.

Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that the Company will host a virtual Key Opinion Leader event on radiotherapy-induced severe oral mucositis in patients with head and neck cancer on Thursday, September 23 at 11:00 a.m. ET.